Zobrazeno 1 - 3
of 3
pro vyhledávání: '"Florine Guillaume"'
Autor:
Vincent Pavot, Hélène Bisceglia, Florine Guillaume, Sandrine Montano, Linong Zhang, Florence Boudet, Jean Haensler
Publikováno v:
Human Vaccines & Immunotherapeutics, Vol 17, Iss 7, Pp 2336-2348 (2021)
Adjuvants are central to the efficacy of subunit vaccines. Although several new adjuvants have been approved in human vaccines over the last decade, the panel of adjuvants in licensed human vaccines remains small. There is still a need for novel adju
Externí odkaz:
https://doaj.org/article/459a2f3556c34dca9f9bd86f75c34c0c
Publikováno v:
Vaccine
The recombinant canarypox virus ALVAC is being extensively studied as vaccine vector for the development of new vaccine strategies against chronic infectious diseases and cancer. However, the mechanisms by which ALVAC initiates the immune response ha
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::ec167cb988ed218772855fde3662aaf6
https://doi.org/10.1016/j.vaccine.2008.07.050
https://doi.org/10.1016/j.vaccine.2008.07.050
Autor:
Michel Becchi, Nathalie Enjolras, Florine Guillaume, Claude Negrier, Eloïse Perot, Yesim Dargaud
Publikováno v:
Thrombosis research. 130(5)
Recombinant factor IX (rFIX) is increasingly used to treat patients with hemophilia B. CHO (Chinese Hamster Ovary) cells are commonly used for the production of rFIX but they have a limited capacity for introducing post-translational modifications (P
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::ac9470ee9e849344ef9ae6463e3f7956
https://pubmed.ncbi.nlm.nih.gov/23021500
https://pubmed.ncbi.nlm.nih.gov/23021500